Cellectar Biosciences, Inc

At close
No trades
See on super-charts

Key stats

Market capitalization
15MUSD
Dividends yield (FY)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
−15.22USD

About Cellectar Biosciences, Inc

ISIN
US15117F8077
CEO
James V. Caruso
Headquarters
Florham Park
Employees
15
Founded
1996

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:
‪0‬
Revenue
‪0‬

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more